Loading
Companies shelve drugs that were safe but failed in the disease they tried. An oncology commons cataloguing discontinued assets with their mechanism, human pharmacokinetics, safety data and reasons for discontinuation, under template access terms, would let others test them where they might work, as NCATS and AstraZeneca schemes have shown.
The NCATS New Therapeutic Uses programme, the AstraZeneca Open Innovation portfolio and the Medical Research Council industry asset-sharing scheme have shown that shelved compounds can be repurposed when made available with their data. An oncology-focused commons with a searchable catalogue of discontinued assets (mechanism, human pharmacokinetics, safety database, reasons for discontinuation) and template access terms would systematise this.
Shares Rescue the biological samples from failed trials for biomarker research, Failures are hidden.
Shares Public post-mortem reports when a cancer drug programme is stopped, Failures are hidden.
Shares Public post-mortem reports when a cancer drug programme is stopped, The valley of death between lab and product, Failures are hidden.
Shares DrugBank & ChEMBL, Failures are hidden.
Shares Rescue the biological samples from failed trials for biomarker research, Failures are hidden.
Shares DrugBank & ChEMBL, The valley of death between lab and product.
Shares Rescue the biological samples from failed trials for biomarker research, Public post-mortem reports when a cancer drug programme is stopped, Failures are hidden.
Shares Public post-mortem reports when a cancer drug programme is stopped, Failures are hidden.